MTOR and sarcoma: Recent clinical trials have combined anti-IGF1R antibody with mammalian target of rapamycin (mTOR) inhibitors after in vitro and in vivo studies combining the two agents in sarcoma cells demonstrated decreased activation of pAKT [29], [30].